Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.49 |
| ▸ | FNTB | P49356 | 6/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.49 |
| ▸ | MME | P08473 | 9/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 9/20 | 0.49 |
| ▸ | ACE | P12821 | 8/20 | 0.49 |
| ▸ | CPA1 | P15085 | 8/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CTSH | P09668 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | NPY4R | P50391 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14509078 | 0.93 | NPY4R (0.47) | MMEACE2ACECPA1CYP1A2 | |
| SCHEMBL14509165 | 0.92 | NPY4R (0.51) | CYP1A2CYP3A4CTSHCYP2D6CTSK | |
| SCHEMBL14531580 | 0.90 | FNTA (0.47) | FNTAFNTBPGGT1BMMEACE2 | |
| SCHEMBL14509124 | 0.90 | FOLH1 (0.50) | MMEACE2ACECPA1GNPAT | |
| SCHEMBL14509063 | 0.86 | NPY4R (0.55) | CYP1A2CYP3A4CTSHCYP2D6CTSK | |
| SCHEMBL1711691 | 0.85 | GNPAT (0.52) | FNTAFNTBPGGT1BGNPATCTSC | |
| SCHEMBL29540393 | 0.85 | GNPAT (0.52) | FNTAFNTBPGGT1BGNPATCTSC | |
| SCHEMBL1711701 | 0.85 | GNPAT (0.52) | FNTAFNTBPGGT1BGNPATCTSC | |
| SCHEMBL5966602 | 0.85 | GNPAT (0.52) | FNTAFNTBPGGT1BGNPATCTSC | |
| SCHEMBL5966594 | 0.85 | GNPAT (0.52) | FNTAFNTBPGGT1BGNPATCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105783-A1 | Process for the manufacture of peptide facilitators of reverse cholesterol transport | SIRCAR JAGADISH C | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105783-A1 | Process for the manufacture of peptide facilitators of reverse cholesterol transport | CETP, NPC1L1, SLC10A1 | FNTA 238/4885FNTB 485/4885PGGT1B 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.